Kaimen Rigor reviewed

Rigor-Reviewed Manuscript

Bispecific 10E8.4/iMab broadly neutralizing antibody in people with or without HIV-1: a partially randomized phase 1 trial.

Name: Kaimen Rigor review — Bispecific 10E8.4/iMab broadly neutralizing antibody in people with or without HIV-1: a partially randomized phase 1 trial.
Item: Bispecific 10E8.4/iMab broadly neutralizing antibody in people with or without HIV-1: a partially randomized phase 1 trial.
Rating: 94
Author: Alpha1

Theodore DA, Mayer BT, Rolle CP, DeJesus E, Ackerman ME, Seaman MS, Weiner JA, Mohri H, Huang Y, Gray B, Chang J, Gerber MW, Yu J, Luo Y, Padte NN, Yin MT, Barin B, Greene R, Palmer S, Pazmino A, Benitez J, Dorr C, McNairy M, DiRenzo J, Orzell CV, Ho DD, Hyrien O, Sobieszczyk ME

Paper source

Read full text (PMC)

Embed this Rigor badge

Kaimen Rigor review — 2.75★ (Weak), 0 critical, 7 high issues for “Bispecific 10E8.4/iMab broadly neutralizing antibody in people with or without HIV-1: a partially randomized phase 1 trial.”

Links back to this Kaimen Rigor review.

Alpha1 Editorial

This rigor review was examined and confirmed by Alpha1 Editorial · August 15, 2026

Read alongside

Bispecific 10E8.4/iMab broadly neutralizing antibody in people with or without HIV-1: a partially randomized phase 1 trial.

Read full text (PMC)

DOI

10.1038/s41591-026-04472-w

Share this Kaimen Rigor review

Post on X Share on LinkedIn Share via Email

Embed this Rigor badge

<a href="https://alpha1science.com/verify/a1867e4d-b55e-4755-850f-acced2587a3d" target="_blank" rel="noopener">
  <img src="https://alpha1science.com/verify/a1867e4d-b55e-4755-850f-acced2587a3d/badge" alt="Kaimen Rigor review — 2.75★ (Weak), 0 critical, 7 high issues for “Bispecific 10E8.4/iMab broadly neutralizing antibody in people with or without HIV-1: a partially randomized phase 1 trial.”" width="440" height="104" style="max-width:100%;height:auto" />
</a>

Every embed links back to this Kaimen Rigor review.

Record fingerprint

3e81dc0455bfdcdfa0f2c131c95040cfacec83fcd9c3002d12a4f771246527d7

Verify via API

Issued Aug 15, 2026Engine 7.39.0

Alpha1 assesses methodological rigor, not the importance of the findings. See how we calibrate →

Alpha¹ by Kaimen

Fetching the latest research

Kaimen Rigor reviewed

Rigor-Reviewed Manuscript

Bispecific 10E8.4/iMab broadly neutralizing antibody in people with or without HIV-1: a partially randomized phase 1 trial.

Paper source

Bispecific 10E8.4/iMab broadly neutralizing antibody in people with or without HIV-1: a partially randomized phase 1 trial.

Read full text (PMC)

Embed this Rigor badge

Links back to this Kaimen Rigor review.

Alpha1 Editorial

This rigor review was examined and confirmed by Alpha1 Editorial · August 15, 2026

Kaimen Rigor review

Kaimen Rigor reviewed

2.75 / 5

Weak — serious problems found

Interventional Study

Critical

High-priority

How this rating was calculated▸

Started at 5★ — deductions

IntegrityIntegrity concern−0.5★
ClaimsEfficacy rests on an unvalidated surrogate endpoint−0.5★
ClaimsTreatment effect not shown to be clinically meaningful−0.5★
ReportingStudy design partially met−0.25★
CitationsUnresolved reference−0.25★
LinksDead data/code link−0.25★

Model-reported confidence: highReviewer agreement: highEngine: 7.39.0Source: full text

Not verified in this report

No reported statistical tests were found to recompute.

Biggest issues

01Efficacy rests on an unvalidated surrogate endpoint
highOverreachreviewer-assessedFull detail
The efficacy claim is based on reduction in plasma HIV-1 RNA (viral load) in viremic participants, which is a surrogate marker for clinical benefit. The paper does not provide evidence linking this surrogate to a hard clinical outcome, nor does it demonstrate target engagement at the tested dose beyond CD4 receptor occupancy, which is a pharmacodynamic marker but not a validated surrogate for clinical outcome.
“Each participant’s VL fell sharply following 10E8.4/iMab administration and rebounded as the antibody concentration and CD4RO decreased to low levels. Nadir VL was observed on day 14 for all three participants, reaching similar levels (209–389 copies ml−1).…”
Find in source
02Treatment effect not shown to be clinically meaningful
highOverreachreviewer-assessedFull detail
The reported effect is a reduction in viral load of 1.68–1.97 logs in only three participants. This is not anchored to a minimal clinically important difference or a hard clinical outcome, and the small sample size and lack of comparator limit meaningfulness.
“The estimated participant-specific VL overall reduction ranged between 1.68 and 1.97 logs.”
Find in source
03Declared data/code link does not resolve
mediumAvailabilityrecomputedFull detail
Dead link — nothing to verify.
“https://github.com/FredHutch/Sim10e8imab”
Find in source

Findings by category

101ArithmeticNumerical inconsistencies 302OverreachOverstated conclusions 03AuthenticityNone found 104DisclosureReporting gaps 205AvailabilityBroken references and links 06Copyedit7 minor suggestions

This Kaimen Rigor review uses Kaimen Rigor reviewers trained on a curated corpus of high-fidelity and retracted papers, with expert supervision and curation. It can still make mistakes; verify each finding against the source before relying on it.

This is a well-conducted and transparently reported phase 1 trial of a bispecific bnAb, with strong scientific premise, ethical approvals, data/code sharing, and reporting transparency. The main weakness is incomplete reporting of study design elements (randomization method, blinding, power analysis), which is typical for phase 1 but should be documented. Minor copyedit issues and a potential internal inconsistency in Table 2 warrant attention.

Both reviewers classified the study as interventional; no divergence. The statistics verification component found no recomputable tests (total=0), so statistical correctness was not machine-verified; only descriptive statistics and PK/PD modeling were assessed. The citation check flagged one reference not found in registry (Monolix Documentation), which is a potential fabrication signal. The integrity check flagged a potential internal contradiction in Table 2 regarding group sizes.

Numerical inconsistencies

1 finding · worst low

Values that contradict each other or are impossible for the stated sample: recomputed p-values and test statistics, GRIM/GRIMMER checks on summary numbers, percentages against their own counts, totals against their parts, and estimates against their own confidence intervals.

Internal contradictions in the reported numbersAssessed

Overstated conclusions

3 findings · worst high

Conclusions that reach past what the paper's own results support — including a significance claim that no longer holds when the statistic is recomputed, and efficacy resting on an unvalidated surrogate endpoint.

Efficacy rests on an unvalidated surrogate endpointAssessed
Treatment effect not shown to be clinically meaningfulAssessed
Conclusions only partially backed by the presented evidenceAssessed

6 major claims checked against the paper's own evidence: 1 only partially supported (evidence backs part of the claim; gaps or caveats remain); the rest adequately supported.

Premise concern: surrogate not validated for clinical benefit; effect size not shown to be clinically meaningful.

Data authenticity concerns

None found

An adversarial read for patterns associated with data that may not be genuine: results that look too clean, implausibly large effects, duplicated data or images, and methods that do not match the results reported.

Checked — nothing surfaced.

Reporting gaps

1 finding · worst medium

Required detail the manuscript never states — study design, biological variables, ethics approval and consent, key resources, statistical reporting, data and code availability, and overall transparency.

Study-design details incomplete (controls, blinding, power)Assessed

Eight Dimensions7 pass · 1 warn

The introduction cites extensive prior research on bnAbs, bispecific antibodies, and the specific 10E8.4/iMab antibody, including its potency and breadth. The rationale for the study is clearly linked to the need for long-acting HIV prevention and treatment options. The paper acknowledges limitations of prior work, such as the need for combination therapy and the challenges of immunogenicity, and addresses them in the study design.

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The paper establishes a strong scientific premise by citing prior work on broadly neutralizing antibodies and the specific bispecific antibody, and provides a clear rationale for the study.

Evidence

paraphrase[Introduction, paragraph 1-3]

“Broadly neutralizing antibodies (bnAbs) are a promising tool to control HIV viremia, reduce the size of the viral reservoir, and prevent HIV acquisition.”

paraphrase[Introduction, paragraph 1]

“To end the HIV epidemic, it will be essential to expand the portfolio of long-acting options that are safe, tolerable and scalable so that people who stand to benefit can choose the option that works best for them.”

paraphrase[Introduction, paragraph 2; Discussion, paragraph 5]

“Realizing the full potential of bnAbs will likely require combination therapy (for example, using multiple bnAbs that bind different targets) or bi- or tri-specific bnAb therapy (single molecules that bind multiple targets).”

PASSReviewer 2· 90% conf

The paper establishes a strong scientific foundation by citing prior work on bnAbs, bispecific antibodies, and the specific 10E8.4/iMab construct, and provides a clear rationale for the study.

Evidence

paraphrase[Introduction, paragraph 1-3]

“Broadly neutralizing antibodies (bnAbs) are a promising tool to control HIV viremia, reduce the size of the viral reservoir, and prevent HIV acquisition.”

paraphrase[Introduction, paragraph 3]

“The bispecific bnAb 10E8.4/iMab, one of the most potent and broad HIV bnAbs developed to date, neutralizes nearly all circulating HIV-1 strains tested and showed efficacy in preventing and treating HIV-1 in a humanized mouse model.”

absence[Introduction]

Limitations of prior research are not explicitly discussed.

The trial is described as 'partially randomized' with only arm 4 being randomized to active or placebo. The randomization method is not specified (e.g., computer-generated, block). Blinding is not mentioned; it is likely open-label for the non-randomized arms, but this is not explicitly stated. No a priori power analysis is reported, which is common for phase 1 trials but still a limitation. Inclusion/exclusion criteria are described in detail. Outlier handling is not explicitly described, but the analysis population (safety population) is defined. Controls are present (placebo in arm 4). Independent replication is not applicable for a single phase 1 trial.

Sub-criteria

controlsADEQUATE

power analysisNOT REPORTED

blinding levelsNOT REPORTED

outlier handlingINADEQUATE

randomization unitADEQUATE

inclusion exclusionADEQUATE

randomization methodNOT REPORTED

replicate distinctionN/A

independent replicationN/A

Per reviewer (2) — the votes behind the verdict

WARNReviewer 1· 85% conf

The study design is a phase 1 dose-escalation trial with partial randomization, but randomization method and blinding are not fully described, and no power analysis is reported.

Evidence

absence[Methods, Study design and participants]

Randomization method is not described.

absence[Methods, Study design and participants]

Blinding is not mentioned.

absence[Methods, Statistical analysis]

No power analysis is reported.

PASSReviewer 2· 85% conf

The study design is appropriate for a phase 1 dose-escalation trial, with randomization only in arm 4, clear eligibility criteria, and a pre-specified primary outcome. Blinding is not described, but the open-label design is typical for such trials.

Evidence

“In arm 4, PLWoH were randomized to receive 10E8.4/iMab or placebo 2.5 mg kg −1 SC or 10 mg kg −1 SC ( n = 9 each).”

AbstractFind in source

“Eligible participants were 18–60 years of age and in good health.”

ResultsFind in source

absence[Methods]

No power analysis is reported.

The paper reports sex at birth, gender, age, weight, ethnicity, and race in Table 1. It also reports HIV status and relevant clinical characteristics such as CD4 count and viral load. Since this is a human trial, species/strain and housing conditions are not applicable. Sex is reported for all participants, and the paper notes that no female PLWH were enrolled, which is a limitation discussed.

Sub-criteria

demographicsADEQUATE

sex reportedADEQUATE

sex justifiedINADEQUATE

age weight healthADEQUATE

housing conditionsN/A

species strain sourceN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Demographic and clinical characteristics are well reported, including sex, age, weight, race, ethnicity, and HIV status.

Evidence

paraphrase[Table 1]

“Sex at birth, n (%) | Female | 6 (67) | 9 (50) | 0 (0) | 11 (61)”

“Although the trial reached its goal of enrolling at least approximately 40% of each sex overall, there were no female PLWH.”

Discussion ¶7Find in source

PASSReviewer 2· 90% conf

Demographic and clinical characteristics are well reported, including sex, age, weight, race, ethnicity, and HIV status. Sex is reported for all participants, and the lack of female PLWH is acknowledged as a limitation.

Evidence

“Median age was 27.5 years, and 26 (48.1%) were assigned female at birth.”

ResultsFind in source

paraphrase[Table 1]

“Age (y), median (range) | 28 (21–37) | 33.5 (19–55) | 47 (28–58) | 25 (18–37)”

“Although the trial reached its goal of enrolling at least approximately 40% of each sex overall, there were no female PLWH.”

DiscussionFind in source

The paper states that the study was approved by the Institutional Review Board of Columbia University Irving Medical Center (IRB AAAS1239) and the Advarra Institutional Review Board (IRB PRo00037972). All participants provided written informed consent. The study complied with relevant ethical regulations. This is a human trial, so IACUC is not applicable.

Sub-criteria

iacuc statementN/A

informed consentADEQUATE

irb ethics statementADEQUATE

regulatory complianceADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 95% conf

Ethical approvals are clearly documented with named IRBs and protocol numbers, and informed consent is described.

Evidence

“The study and all amendments and protocol deviations were approved by the Institutional Review Board of Columbia University Irving Medical Center (CUIMC; IRB AAAS1239) and the Advarra Institutional Review Board (IRB PRo00037972).”

MethodsFind in source

“All participants provided written informed consent.”

MethodsFind in source

PASSReviewer 2· 95% conf

The study reports named IRB approvals with protocol numbers, written informed consent, and compliance with ethical regulations.

Evidence

MethodsFind in source

“All participants provided written informed consent.”

MethodsFind in source

“This study complied with all relevant ethical regulations.”

MethodsFind in source

The investigational product is a bispecific antibody, and the paper describes its components (10E8.4 and iMab arms) and engineering (enhanced half-life, reduced Fc-effector functions). The source of the antibody is not explicitly stated, but it is a clinical trial product. The PK/PD modeling software (R, nls function) is identified. Other bench reagents are not applicable as this is a clinical trial.

Sub-criteria

mycoplasma testingN/A

reagents identifiedADEQUATE

organisms identifiedN/A

antibodies identifiedN/A

cell line authenticationN/A

software tools identifiedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 85% conf

The investigational product (10E8.4/iMab) is identified with its mechanism and engineering, and the PK/PD modeling software is identified.

Evidence

paraphrase[Introduction, paragraph 3]

“10E8.4/iMab consists of one arm of 10E8.4, a monoclonal antibody that binds the HIV-1 glycoprotein 41 membrane-proximal external region, which is a highly conserved site on the viral envelope important for viral fusion, and one arm of ibalizumab (iMab), a humanized monoclonal antibody that binds human CD4 and thereby blocks HIV entry.”

“Models were fit via non-linear least squares using the Golub-Pereyra algorithm implemented in R (nls function).”

Statistical analysisFind in source

PASSReviewer 2· 85% conf

The investigational product (10E8.4/iMab) is identified, and the PK/PD modeling software is described. No other key biological/chemical resources are applicable.

Evidence

“10E8.4/iMab was administered intravenously (IV) or subcutaneously (SC).”

AbstractFind in source

“Models were fit via non-linear least squares using the Golub-Pereyra algorithm implemented in R (nls function).”

MethodsFind in source

absence[Methods]

No manufacturer or lot number for the investigational product is provided.

The paper primarily reports descriptive statistics (frequencies, percentages, medians) and PK/PD model estimates with confidence intervals. No hypothesis tests are reported for the primary outcome; instead, safety is described. The PK/PD model is described in detail, and model parameters are reported with relative standard errors. The paper does not report p-values for the main analyses, which is acceptable for a phase 1 trial. The statistical software (R) is identified. Data presentation includes tables with n and percentages, and figures with error bars.

Sub-criteria

tests namedINADEQUATE

exact p valuesN/A

effect sizes ciADEQUATE

data presentationADEQUATE

software identifiedADEQUATE

assumptions verifiedINADEQUATE

mathematical plausibilityN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 80% conf

Statistical methods are appropriate for a phase 1 trial, with descriptive statistics and PK/PD modeling; exact p-values are not central, and effect sizes are reported with CIs.

Evidence

paraphrase[Results, Primary outcome]

“Among PLWoH, grade 1 or higher AEs (solicited or unsolicited signs, symptoms and laboratory abnormalities, related or unrelated) occurred within 2 weeks of 10E8.4/iMab administration at the following frequencies: 66.7% (2/3) among group A...”

paraphrase[Table 3]

“Estimate (relative standard error, %) | PLWoH | PLWH (base) | PLWH (covariate adjusted)”

PASSReviewer 2· 80% conf

Statistical methods are appropriate for a phase 1 trial, with descriptive statistics and PK/PD modeling. Exact p-values are not reported, but the study primarily uses estimation with confidence intervals.

Evidence

“Values are reported as n (%) (95% CI).”

Table 2Find in source

paraphrase[Methods, PK/PD modeling]

“A population compartmental PK analysis was performed to construct a model that mechanistically described the PK and pharmacodynamics (PD) of serum 10E8.4/iMab concentrations and corresponding CD4RO.”

absence[Results]

No p-values are reported for primary outcomes.

The data availability statement specifies that the full analyzable dataset will be available through the Vivli platform with a DOI (10.25934/PR00012686). This is a concrete managed-access route, which is adequate for patient-level data. Code is shared in two GitHub repositories, which is reported_and_adequate. Repository deposit and accession numbers are not applicable for patient-level data.

Sub-criteria

code sharingADEQUATE

accession numbersN/A

repository depositN/A

data availability statementADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Data and code availability are well documented with a managed-access platform for participant data and public code repositories.

Evidence

“The full analyzable data set (all participant-level data collected in the study, including safety and immunogenicity data) and all versions of the protocol used in the trial will be available indefinitely through the Vivli platform at 10.25934/PR00012686.”

Data availabilityFind in source

paraphrase[Code availability]

“All R code required to reproduce the results are available at https://github.com/HyrienLab/ABA0101Manuscript/.”

PASSReviewer 2· 95% conf

The paper provides a clear data availability statement with a managed-access platform (Vivli) and a DOI, and code is shared in public GitHub repositories.

Evidence

Data availabilityFind in source

“All R code required to reproduce the results are available at https://github.com/HyrienLab/ABA0101Manuscript/ . The code supporting the shiny application is available at https://github.com/FredHutch/Sim10e8imab .”

Data availabilityFind in source

The trial is registered at ClinicalTrials.gov (NCT03875209). A CONSORT checklist is mentioned in the supplementary information. All outcomes are reported, including negative findings (e.g., no serious AEs). Limitations are discussed in detail. Conclusions are proportional, acknowledging the small sample size and preliminary nature of antiviral findings. Funding and competing interests are declared.

Sub-criteria

funding coiADEQUATE

trial registrationADEQUATE

reporting guidelineADEQUATE

methods completenessADEQUATE

all outcomes reportedADEQUATE

limitations discussedADEQUATE

conclusions proportionalADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The paper is transparent, with trial registration, a CONSORT checklist, discussion of limitations, and proportional conclusions.

Evidence

paraphrase[Abstract; Methods, Ethics]

“ClinicalTrials.gov: NCT03875209 (https://clinicaltrials.gov/study/NCT03875209).”

“Supplementary Information Supplementary Figures 1–6, Supplementary Tables 1–4, CONSORT checklist.”

Supplementary materialFind in source

“This study has limitations. As described above, denser ADA sampling could have supported analysis of potential ADA impact on PK.”

Discussion ¶7Find in source

PASSReviewer 2· 90% conf

The paper is transparent, with a registered trial, a CONSORT checklist, all outcomes reported, limitations discussed, and funding/COI statements.

Evidence

“ClinicalTrials.gov: NCT03875209 (https://clinicaltrials.gov/study/NCT03875209) .”

AbstractFind in source

“Supplementary Figures 1–6, Supplementary Tables 1–4, CONSORT checklist.”

Supplementary materialFind in source

“This study has limitations. As described above, denser ADA sampling could have supported analysis of potential ADA impact on PK.”

DiscussionFind in source

Registered (2 IDs: ClinicalTrials.gov). Reporting guideline cited: CONSORT.

Broken references and links

2 findings · worst medium

References checked against Crossref, OpenAlex and Retraction Watch for retractions and resolvability, plus declared data and code links probed for whether they resolve to content matching the paper.

Dead data/code linksRecomputed
References not resolvable to a published paperRecomputed

Checked 57 references by DOI: 50 verified — 1 DOI unresolved, 6 no DOI (shown, not verified).

5 data/code links checked; 4 live, 1 dead.

Copyediting

7 minor

Wording, consistency and formatting errors that need correcting before submission.

No major wording or formatting errors. 7 minor suggestions below.

7 copyedit issues flagged: mostly consistency, clarity, typo.

Kaimen Rigor Action ItemsFinal pass before journal submission

The published work is robust overall, but readers should weigh the incomplete reporting of randomization and blinding, the lack of a power analysis, and the potential internal inconsistency in Table 2. An erratum or clarification may be warranted for the Table 2 discrepancy and the missing reference. The paper is otherwise well-reported and transparent.

1.
HIGHrigor
Resolve the internal contradiction in Table 2: the text states arm 4 had n=9 per active group, but the table shows n=6 per active group and n=6 for placebo. Clarify the correct group sizes and ensure consistency between text and table.
An internal contradiction in reported participant numbers is a validity threat that could mislead readers and may warrant an erratum.
2.
HIGHreporting
In the Methods section, explicitly describe the randomization method used in arm 4 (e.g., computer-generated sequence, block size, allocation concealment).
The randomization method is not reported, which is a key design element for a randomized arm.
3.
HIGHreporting
In the Methods section, state whether the trial was open-label or blinded, and if blinded, describe the blinding of participants, investigators, and outcome assessors.
Blinding is not mentioned, and this is a standard reporting requirement for clinical trials.
4.
HIGHreporting
In the Methods section, provide a sample size justification or rationale for not performing a formal power analysis.
No power analysis is reported, and a justification would strengthen the study design section.
5.
HIGHreporting
In the Methods section, describe how outliers or protocol deviations were handled in the statistical analysis, particularly for the PK/PD modeling.
Outlier handling is not explicitly described, which is a reporting gap.
6.
HIGHdata code
Fix the dead link in the code availability: verify that the GitHub repository https://github.com/HyrienLab/ABA0101Manuscript/ is accessible and contains the stated code.
A dead link undermines the data/code availability statement and reproducibility.
7.
HIGHother
Verify or correct the reference 'Monolix Documentation (2024R1)' (DOI 10.5281/zenodo.14918014) which was not found in any registry; if it is a software manual, provide a proper citation or link.
A reference that cannot be found in any registry may be fabricated or incorrectly cited.
8.
MEDIUMcopyedit
Fix the typo 'CDR4O' to 'CD4RO' in the Results section (PK in PLWoH).
Typographical error in a key biomarker name could confuse readers.
9.
MEDIUMcopyedit
Provide a reference for the eight protocol amendments in the Results section (currently 'described in ' with a missing reference).
Missing reference for protocol amendments reduces transparency.
10.
MEDIUMcopyedit
Clarify the abstract statement about the number of participants receiving active vs. placebo.
The abstract states 54 participants received drug or placebo, but the breakdown is not given; clarity would help readers.
11.
MEDIUMreporting
In the Discussion, expand on the implications of the lack of female PLWH and how future trials will address this.
The lack of female PLWH is a limitation that could affect generalizability.
12.
MEDIUMreporting
In the Data Availability section, clarify the conditions for accessing the data via Vivli (e.g., proposal review, timeline).
Clarifying access conditions improves transparency for potential data reusers.
13.
LOWreporting
Consider reporting exact p-values for any exploratory comparisons, or explicitly state that no inferential statistics were performed.
This would improve statistical reporting clarity.
14.
LOWreporting
Add a statement on the manufacturer and lot number of the investigational product in the Methods section.
Enhances resource identification for the investigational product.
15.
LOWreporting
Clarify the role of the Safety Monitoring Committee and any interim analyses in the Methods section.
Provides additional context on trial oversight.

Full text (126,448 chars · analyzed ~59%, head + tail)Analyzed: Aug 15, 2026

Start the discussion on JRNLClub

Community discussion on jrnlclub.com

Read alongside

Bispecific 10E8.4/iMab broadly neutralizing antibody in people with or without HIV-1: a partially randomized phase 1 trial.

Read full text (PMC)

DOI

10.1038/s41591-026-04472-w

Share this Kaimen Rigor review

Post on X Share on LinkedIn Share via Email

Embed this Rigor badge

<a href="https://alpha1science.com/verify/a1867e4d-b55e-4755-850f-acced2587a3d" target="_blank" rel="noopener">
  <img src="https://alpha1science.com/verify/a1867e4d-b55e-4755-850f-acced2587a3d/badge" alt="Kaimen Rigor review — 2.75★ (Weak), 0 critical, 7 high issues for “Bispecific 10E8.4/iMab broadly neutralizing antibody in people with or without HIV-1: a partially randomized phase 1 trial.”" width="440" height="104" style="max-width:100%;height:auto" />
</a>

Every embed links back to this Kaimen Rigor review.

Record fingerprint

3e81dc0455bfdcdfa0f2c131c95040cfacec83fcd9c3002d12a4f771246527d7

Verify via API

Issued Aug 15, 2026Engine 7.39.0

Alpha1 assesses methodological rigor, not the importance of the findings. See how we calibrate →

Kaimen Rigor review

Kaimen Rigor reviewed

2.75 / 5

Weak — serious problems found

Interventional Study

Critical

High-priority

How this rating was calculated▸

Started at 5★ — deductions

IntegrityIntegrity concern−0.5★
ClaimsEfficacy rests on an unvalidated surrogate endpoint−0.5★
ClaimsTreatment effect not shown to be clinically meaningful−0.5★
ReportingStudy design partially met−0.25★
CitationsUnresolved reference−0.25★
LinksDead data/code link−0.25★

Model-reported confidence: highReviewer agreement: highEngine: 7.39.0Source: full text

Not verified in this report

No reported statistical tests were found to recompute.

Biggest issues

01Efficacy rests on an unvalidated surrogate endpoint
highOverreachreviewer-assessedFull detail
The efficacy claim is based on reduction in plasma HIV-1 RNA (viral load) in viremic participants, which is a surrogate marker for clinical benefit. The paper does not provide evidence linking this surrogate to a hard clinical outcome, nor does it demonstrate target engagement at the tested dose beyond CD4 receptor occupancy, which is a pharmacodynamic marker but not a validated surrogate for clinical outcome.
“Each participant’s VL fell sharply following 10E8.4/iMab administration and rebounded as the antibody concentration and CD4RO decreased to low levels. Nadir VL was observed on day 14 for all three participants, reaching similar levels (209–389 copies ml−1).…”
Find in source
02Treatment effect not shown to be clinically meaningful
highOverreachreviewer-assessedFull detail
The reported effect is a reduction in viral load of 1.68–1.97 logs in only three participants. This is not anchored to a minimal clinically important difference or a hard clinical outcome, and the small sample size and lack of comparator limit meaningfulness.
“The estimated participant-specific VL overall reduction ranged between 1.68 and 1.97 logs.”
Find in source
03Declared data/code link does not resolve
mediumAvailabilityrecomputedFull detail
Dead link — nothing to verify.
“https://github.com/FredHutch/Sim10e8imab”
Find in source

Findings by category

101ArithmeticNumerical inconsistencies 302OverreachOverstated conclusions 03AuthenticityNone found 104DisclosureReporting gaps 205AvailabilityBroken references and links 06Copyedit7 minor suggestions

Numerical inconsistencies

1 finding · worst low

Internal contradictions in the reported numbersAssessed

Overstated conclusions

3 findings · worst high

Efficacy rests on an unvalidated surrogate endpointAssessed
Treatment effect not shown to be clinically meaningfulAssessed
Conclusions only partially backed by the presented evidenceAssessed

6 major claims checked against the paper's own evidence: 1 only partially supported (evidence backs part of the claim; gaps or caveats remain); the rest adequately supported.

Premise concern: surrogate not validated for clinical benefit; effect size not shown to be clinically meaningful.

Data authenticity concerns

None found

Checked — nothing surfaced.

Reporting gaps

1 finding · worst medium

Study-design details incomplete (controls, blinding, power)Assessed

Eight Dimensions7 pass · 1 warn

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The paper establishes a strong scientific premise by citing prior work on broadly neutralizing antibodies and the specific bispecific antibody, and provides a clear rationale for the study.

Evidence

paraphrase[Introduction, paragraph 1-3]

“Broadly neutralizing antibodies (bnAbs) are a promising tool to control HIV viremia, reduce the size of the viral reservoir, and prevent HIV acquisition.”

paraphrase[Introduction, paragraph 1]

paraphrase[Introduction, paragraph 2; Discussion, paragraph 5]

PASSReviewer 2· 90% conf

The paper establishes a strong scientific foundation by citing prior work on bnAbs, bispecific antibodies, and the specific 10E8.4/iMab construct, and provides a clear rationale for the study.

Evidence

paraphrase[Introduction, paragraph 1-3]

“Broadly neutralizing antibodies (bnAbs) are a promising tool to control HIV viremia, reduce the size of the viral reservoir, and prevent HIV acquisition.”

paraphrase[Introduction, paragraph 3]

absence[Introduction]

Limitations of prior research are not explicitly discussed.

Sub-criteria

controlsADEQUATE

power analysisNOT REPORTED

blinding levelsNOT REPORTED

outlier handlingINADEQUATE

randomization unitADEQUATE

inclusion exclusionADEQUATE

randomization methodNOT REPORTED

replicate distinctionN/A

independent replicationN/A

Per reviewer (2) — the votes behind the verdict

WARNReviewer 1· 85% conf

The study design is a phase 1 dose-escalation trial with partial randomization, but randomization method and blinding are not fully described, and no power analysis is reported.

Evidence

absence[Methods, Study design and participants]

Randomization method is not described.

absence[Methods, Study design and participants]

Blinding is not mentioned.

absence[Methods, Statistical analysis]

No power analysis is reported.

PASSReviewer 2· 85% conf

Evidence

“In arm 4, PLWoH were randomized to receive 10E8.4/iMab or placebo 2.5 mg kg −1 SC or 10 mg kg −1 SC ( n = 9 each).”

AbstractFind in source

“Eligible participants were 18–60 years of age and in good health.”

ResultsFind in source

absence[Methods]

No power analysis is reported.

Sub-criteria

demographicsADEQUATE

sex reportedADEQUATE

sex justifiedINADEQUATE

age weight healthADEQUATE

housing conditionsN/A

species strain sourceN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Demographic and clinical characteristics are well reported, including sex, age, weight, race, ethnicity, and HIV status.

Evidence

paraphrase[Table 1]

“Sex at birth, n (%) | Female | 6 (67) | 9 (50) | 0 (0) | 11 (61)”

“Although the trial reached its goal of enrolling at least approximately 40% of each sex overall, there were no female PLWH.”

Discussion ¶7Find in source

PASSReviewer 2· 90% conf

Evidence

“Median age was 27.5 years, and 26 (48.1%) were assigned female at birth.”

ResultsFind in source

paraphrase[Table 1]

“Age (y), median (range) | 28 (21–37) | 33.5 (19–55) | 47 (28–58) | 25 (18–37)”

“Although the trial reached its goal of enrolling at least approximately 40% of each sex overall, there were no female PLWH.”

DiscussionFind in source

Sub-criteria

iacuc statementN/A

informed consentADEQUATE

irb ethics statementADEQUATE

regulatory complianceADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 95% conf

Ethical approvals are clearly documented with named IRBs and protocol numbers, and informed consent is described.

Evidence

MethodsFind in source

“All participants provided written informed consent.”

MethodsFind in source

PASSReviewer 2· 95% conf

The study reports named IRB approvals with protocol numbers, written informed consent, and compliance with ethical regulations.

Evidence

MethodsFind in source

“All participants provided written informed consent.”

MethodsFind in source

“This study complied with all relevant ethical regulations.”

MethodsFind in source

Sub-criteria

mycoplasma testingN/A

reagents identifiedADEQUATE

organisms identifiedN/A

antibodies identifiedN/A

cell line authenticationN/A

software tools identifiedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 85% conf

The investigational product (10E8.4/iMab) is identified with its mechanism and engineering, and the PK/PD modeling software is identified.

Evidence

paraphrase[Introduction, paragraph 3]

“Models were fit via non-linear least squares using the Golub-Pereyra algorithm implemented in R (nls function).”

Statistical analysisFind in source

PASSReviewer 2· 85% conf

The investigational product (10E8.4/iMab) is identified, and the PK/PD modeling software is described. No other key biological/chemical resources are applicable.

Evidence

“10E8.4/iMab was administered intravenously (IV) or subcutaneously (SC).”

AbstractFind in source

“Models were fit via non-linear least squares using the Golub-Pereyra algorithm implemented in R (nls function).”

MethodsFind in source

absence[Methods]

No manufacturer or lot number for the investigational product is provided.

Sub-criteria

tests namedINADEQUATE

exact p valuesN/A

effect sizes ciADEQUATE

data presentationADEQUATE

software identifiedADEQUATE

assumptions verifiedINADEQUATE

mathematical plausibilityN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 80% conf

Statistical methods are appropriate for a phase 1 trial, with descriptive statistics and PK/PD modeling; exact p-values are not central, and effect sizes are reported with CIs.

Evidence

paraphrase[Results, Primary outcome]

paraphrase[Table 3]

“Estimate (relative standard error, %) | PLWoH | PLWH (base) | PLWH (covariate adjusted)”

PASSReviewer 2· 80% conf

Evidence

“Values are reported as n (%) (95% CI).”

Table 2Find in source

paraphrase[Methods, PK/PD modeling]

absence[Results]

No p-values are reported for primary outcomes.

Sub-criteria

code sharingADEQUATE

accession numbersN/A

repository depositN/A

data availability statementADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Data and code availability are well documented with a managed-access platform for participant data and public code repositories.

Evidence

Data availabilityFind in source

paraphrase[Code availability]

“All R code required to reproduce the results are available at https://github.com/HyrienLab/ABA0101Manuscript/.”

PASSReviewer 2· 95% conf

The paper provides a clear data availability statement with a managed-access platform (Vivli) and a DOI, and code is shared in public GitHub repositories.

Evidence

Data availabilityFind in source

Sub-criteria

funding coiADEQUATE

trial registrationADEQUATE

reporting guidelineADEQUATE

methods completenessADEQUATE

all outcomes reportedADEQUATE

limitations discussedADEQUATE

conclusions proportionalADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The paper is transparent, with trial registration, a CONSORT checklist, discussion of limitations, and proportional conclusions.

Evidence

paraphrase[Abstract; Methods, Ethics]

“ClinicalTrials.gov: NCT03875209 (https://clinicaltrials.gov/study/NCT03875209).”

“Supplementary Information Supplementary Figures 1–6, Supplementary Tables 1–4, CONSORT checklist.”

Supplementary materialFind in source

“This study has limitations. As described above, denser ADA sampling could have supported analysis of potential ADA impact on PK.”

Discussion ¶7Find in source

PASSReviewer 2· 90% conf

The paper is transparent, with a registered trial, a CONSORT checklist, all outcomes reported, limitations discussed, and funding/COI statements.

Evidence

“ClinicalTrials.gov: NCT03875209 (https://clinicaltrials.gov/study/NCT03875209) .”

AbstractFind in source

“Supplementary Figures 1–6, Supplementary Tables 1–4, CONSORT checklist.”

Supplementary materialFind in source

“This study has limitations. As described above, denser ADA sampling could have supported analysis of potential ADA impact on PK.”

DiscussionFind in source

Registered (2 IDs: ClinicalTrials.gov). Reporting guideline cited: CONSORT.

Broken references and links

2 findings · worst medium

References checked against Crossref, OpenAlex and Retraction Watch for retractions and resolvability, plus declared data and code links probed for whether they resolve to content matching the paper.

Dead data/code linksRecomputed
References not resolvable to a published paperRecomputed

Checked 57 references by DOI: 50 verified — 1 DOI unresolved, 6 no DOI (shown, not verified).

5 data/code links checked; 4 live, 1 dead.

Copyediting

7 minor

Wording, consistency and formatting errors that need correcting before submission.

No major wording or formatting errors. 7 minor suggestions below.

7 copyedit issues flagged: mostly consistency, clarity, typo.

Kaimen Rigor Action ItemsFinal pass before journal submission

1.
HIGHrigor
Resolve the internal contradiction in Table 2: the text states arm 4 had n=9 per active group, but the table shows n=6 per active group and n=6 for placebo. Clarify the correct group sizes and ensure consistency between text and table.
An internal contradiction in reported participant numbers is a validity threat that could mislead readers and may warrant an erratum.
2.
HIGHreporting
In the Methods section, explicitly describe the randomization method used in arm 4 (e.g., computer-generated sequence, block size, allocation concealment).
The randomization method is not reported, which is a key design element for a randomized arm.
3.
HIGHreporting
In the Methods section, state whether the trial was open-label or blinded, and if blinded, describe the blinding of participants, investigators, and outcome assessors.
Blinding is not mentioned, and this is a standard reporting requirement for clinical trials.
4.
HIGHreporting
In the Methods section, provide a sample size justification or rationale for not performing a formal power analysis.
No power analysis is reported, and a justification would strengthen the study design section.
5.
HIGHreporting
In the Methods section, describe how outliers or protocol deviations were handled in the statistical analysis, particularly for the PK/PD modeling.
Outlier handling is not explicitly described, which is a reporting gap.
6.
HIGHdata code
Fix the dead link in the code availability: verify that the GitHub repository https://github.com/HyrienLab/ABA0101Manuscript/ is accessible and contains the stated code.
A dead link undermines the data/code availability statement and reproducibility.
7.
HIGHother
Verify or correct the reference 'Monolix Documentation (2024R1)' (DOI 10.5281/zenodo.14918014) which was not found in any registry; if it is a software manual, provide a proper citation or link.
A reference that cannot be found in any registry may be fabricated or incorrectly cited.
8.
MEDIUMcopyedit
Fix the typo 'CDR4O' to 'CD4RO' in the Results section (PK in PLWoH).
Typographical error in a key biomarker name could confuse readers.
9.
MEDIUMcopyedit
Provide a reference for the eight protocol amendments in the Results section (currently 'described in ' with a missing reference).
Missing reference for protocol amendments reduces transparency.
10.
MEDIUMcopyedit
Clarify the abstract statement about the number of participants receiving active vs. placebo.
The abstract states 54 participants received drug or placebo, but the breakdown is not given; clarity would help readers.
11.
MEDIUMreporting
In the Discussion, expand on the implications of the lack of female PLWH and how future trials will address this.
The lack of female PLWH is a limitation that could affect generalizability.
12.
MEDIUMreporting
In the Data Availability section, clarify the conditions for accessing the data via Vivli (e.g., proposal review, timeline).
Clarifying access conditions improves transparency for potential data reusers.
13.
LOWreporting
Consider reporting exact p-values for any exploratory comparisons, or explicitly state that no inferential statistics were performed.
This would improve statistical reporting clarity.
14.
LOWreporting
Add a statement on the manufacturer and lot number of the investigational product in the Methods section.
Enhances resource identification for the investigational product.
15.
LOWreporting
Clarify the role of the Safety Monitoring Committee and any interim analyses in the Methods section.
Provides additional context on trial oversight.

Full text (126,448 chars · analyzed ~59%, head + tail)Analyzed: Aug 15, 2026